Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 2/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1328863 | 1.00 | MAPT (0.50) | MAPTANPEPDPP8DPP7DPP4 | |
| SCHEMBL2562513 | 0.90 | MAPT (0.49) | MAPTANPEPDPP8DPP7DPP4 | |
| SCHEMBL10242708 | 0.88 | KLK7 (0.54) | MAPTMEN1KMT2AKLK7KLK5 | |
| SCHEMBL12127588 | 0.86 | CA1 (0.55) | MAPTMEN1KMT2AKLK7KLK5 | |
| SCHEMBL29229822 | 0.86 | SYK (0.53) | MAPTFOLH1SYKL3MBTL1 | |
| SCHEMBL12287162 | 0.84 | KLK7 (0.49) | MAPTMEN1KMT2AKLK7KLK5 | |
| SCHEMBL2584353 | 0.84 | KLK7 (0.49) | MAPTMEN1KMT2AKLK7KLK5 | |
| SCHEMBL13851530 | 0.84 | SYK (0.51) | MAPTFOLH1MEN1KMT2ASYK | |
| SCHEMBL18879557 | 0.84 | ANPEP (0.52) | MAPTANPEPDPP8DPP7DPP4 | |
| SCHEMBL5490556 | 0.83 | MAPT (0.59) | MAPTANPEPDPP8DPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560489-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2560490-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | Signature Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133151-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PHENOL-MODIFIED OPIOID PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133149-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133150-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PEPD, TMPRSS15, ADAM17 | MAPT 2944/4885ANPEP 31/4885DPP8 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.